Advertisement

Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCV

  • G. Diodati
  • P. Bonetti
  • A. Tagger
  • A. Alberti
  • G. Realdi
  • A. Ruol
Part of the Archives of Virology book series (ARCHIVES SUPPL, volume 4)

Summary

In a randomized controlled trial of Interferon (IFN) in 60 patients (30 treated and 30 controls) with cryptogenic chronic active liver disease, 70% of treated patients showed complete response, but a high rate of biochemical relapse (62%) was noted. In these cases, a second response to higher doses of IFN has been more difficult and less frequent. A response to IFN was found in 88.5% of anti-HCV positive treated patients and only in 25% of anti-HCV negative. We suggest that serum anti-HCV is a suitable test to predict the response to IFN.

Keywords

Chronic Active Hepatitis Interferon Therapy Biochemical Relapse Decompensated Liver Cirrhosis Chronic Active Liver Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alter MJ (1989) NonA, nonB hepatitis: sorting through a diagnosis of exclusion. Ann Intern Med 110: 583–585PubMedGoogle Scholar
  2. 2.
    Hoofnagle JH, Mullen KD, Jones B, et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1573–1578CrossRefGoogle Scholar
  3. 3.
    Jacyna MR, Brooks MG, Loke RHT, et al (1989) Randomized controlled trial of Interferon alpha (lymphoblastoid Interferon) in chronic non-A, non-B hepatitis. Br Med J 298: 80–82CrossRefGoogle Scholar
  4. 4.
    Choo QL, Kuo G, Weiner AJ, et al (1989) Isolation of a cDNA derived from a blood borne non-A, non-B viral hepatitis genome. Science 244: 359–362PubMedCrossRefGoogle Scholar
  5. 5.
    Kuo G, Choo QL, Alter HJ, et al (1989) An assay for circulating antibodies to a major etiologic virus of non-A, non-B hepatitis. Science 244: 362–364PubMedCrossRefGoogle Scholar
  6. 6.
    Fattovich G, Brollo L, Boscaro S, et al (1989) Long-term effect of low dose recombinant Interferon therapy in patients with chronic hepatitis B. J Hepatol 9: 331–337PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • G. Diodati
    • 1
    • 4
  • P. Bonetti
    • 1
  • A. Tagger
    • 2
  • A. Alberti
    • 1
  • G. Realdi
    • 3
  • A. Ruol
    • 1
  1. 1.Istituto di Medicina InternaUniversity di PadovaItaly
  2. 2.Istituto di VirologiaUniversity di MilanoItaly
  3. 3.Clinica Medica GeneraleUniversity di SassariItaly
  4. 4.Istituto di Medicina Clinica, Clinica Medica 2Policlinico — UniversitàPadovaItaly

Personalised recommendations